Mounjaro (tirzepatide): Complete Guide 2026
Mounjaro (tirzepatide) is a first-in-class dual GIP/GLP-1 receptor agonist approved for type 2 diabetes. Unlike other GLP-1 medications that target only one receptor, Mounjaro activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing superior blood sugar control and remarkable weight loss. In the SURMOUNT trials, tirzepatide demonstrated weight loss of 21-25%, surpassing all previously approved medications.
Enzo's Tip
Mounjaro is the new kid on the block and it packs a serious punch! Enzo is impressed — two receptors are better than one, just like two cat naps are better than one. Remember, the dose escalation takes time, so settle in and let the magic happen! 🐾
Track your Mounjaro journey with Enzo
Dose tracking, side effect logging, and a cute cat cheering you on. Free to download.
Quick Facts
| Generic Name | tirzepatide |
| Manufacturer | Eli Lilly |
| Type | Injectable pen |
| Frequency | Once weekly |
| Primary Indication | Type 2 diabetes |
Mounjaro Guides
Get Mounjaro prescribed online — most patients approved in 24 hours
Licensed providers, no in-person visit, medication shipped to your door.
Enzo reminds you when your next Mounjaro dose is due
Dose tracking, side effect logging, and a cute cat cheering you on. Free to download.
Frequently Asked Questions
The guide your doctor doesn't have time to give you
Your complete Mounjaro playbook: week-by-week guide, what to eat when nothing sounds good, and how to manage every side effect. Free.
No spam. Unsubscribe anytime.
Medical Disclaimer: Enzo is a tracking companion, not a doctor. Always consult your healthcare provider before starting, stopping, or changing any medication. The information on this page is for educational purposes only and should not be considered medical advice. Individual results may vary.